<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR5">
 <label>5.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Robert</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Ribas</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Schachter</surname>
    <given-names>J</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study</article-title>
  <source>Lancet Oncol</source>
  <year>2019</year>
  <volume>20</volume>
  <issue>9</issue>
  <fpage>1239</fpage>
  <lpage>1251</lpage>
  <pub-id pub-id-type="doi">10.1016/S1470-2045(19)30388-2</pub-id>
  <?supplied-pmid 31345627?>
  <pub-id pub-id-type="pmid">31345627</pub-id>
 </element-citation>
</ref>
